Victory Capital Management Inc Altimmune, Inc. Transaction History

Victory Capital Management Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 07, 2020	SELL	$2.9 - $10.71 $6,780 - $25,039	-2,338 Closed	0 $0
Q1 2020 May 04, 2020	SELL	$1.69 - $3.8 $89 - $201	-53 Reduced 2.22%	2,338 $8,000
Q4 2019 Feb 04, 2020	BUY	$1.53 - $2.15 $100 - $141	66 Added 2.84%	2,391 $4,000
Q3 2019 Nov 12, 2019	BUY	$1.95 - $2.66 $4,533 - $6,184	2,325 New	2,325 $5,000

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $428M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Victory Capital Management Inc with notifications on news.